Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Musculoskeletal Diseases AND Autoimmune Diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44399   clinical trials with a EudraCT protocol, of which   7411   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    53 result(s) found for: Musculoskeletal Diseases AND Autoimmune Diseases. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2021-001671-16 Sponsor Protocol Number: ACT17209 Start Date*: 2021-10-08
    Sponsor Name:Sanofi aventis recherche et developpement
    Full Title: A multicenter, open-label, Phase IIb study to evaluate the efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia
    Medical condition: Warm autoimmune hemolytic anemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10073785 Autoimmune haemolytic anaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DK (Trial now transitioned) IT (Trial now transitioned) HU (Completed) DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002245-15 Sponsor Protocol Number: CCM-RNT-202102 Start Date*: 2021-05-25
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: A low-interventional study to investigate the efficacy and safety of SARS-CoV-2 vaccines in patients with rheumatic diseases.
    Medical condition: Auto Immune Rheumatic Diseases (AIRD) and patients without rheumatic autoimmune diseases (control group).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10072736 Rheumatic disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003880-24 Sponsor Protocol Number: ACT16832 Start Date*: 2021-03-24
    Sponsor Name:Sanofi-Aventis Recherche & Developpement
    Full Title: A multicenter, open-label, non-randomized, Phase 1b/2 study to evaluate the safety, pharmacokinetics,and efficacy of subcutaneous isatuximab in adults with warm autoimmune hemolytic anemia
    Medical condition: Warm autoimmune hemolytic anemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10047822 Warm type haemolytic anaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) HU (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005772-34 Sponsor Protocol Number: CL2-78989-010 Start Date*: 2013-06-17
    Sponsor Name:Institut de Recherches Internationales Servier (IRIS)
    Full Title: A randomised, double-blind, placebo-controlled proof-of concept study of the efficacy of gevokizumab 60mg subcutaneously every 4 weeks over 24 weeks in the treatment of patients with polymyositis o...
    Medical condition: Polymyositis / Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10036102 Polymyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) SE (Completed) DE (Prematurely Ended) CZ (Completed) GB (Prematurely Ended) ES (Completed) HU (Completed) BE (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000609-58 Sponsor Protocol Number: NN8226-3612 Start Date*: 2013-02-20
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003131-31 Sponsor Protocol Number: M19-956 Start Date*: 2020-02-05
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2a, Double-Blind, Randomized, Placebo-Controlled Study of Ravagalimab in Subjects with Moderately to Severely Active Primary Sjogren’s Syndrome.
    Medical condition: Moderately to Severely Active Primary Sjogren's Syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004419-35 Sponsor Protocol Number: GN13RH410 Start Date*: 2015-03-18
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: Inhibition of Co-Stimulation in Rheumatoid Arthritis
    Medical condition: Rheumatoid Arthritis: patients who are dual ACPA and HLA-DR4 positive
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-004568-25 Sponsor Protocol Number: BLAST Start Date*: 2021-08-18
    Sponsor Name:DIPARTIMENTO DI SCIENZE CLINICHE E BIOLOGICHE (UNITO)
    Full Title: Open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory and/or non-criteria manifestations of Antiphospholipid Syndrome.
    Medical condition: APS
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10002817 Antiphospholipid syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-000895-40 Sponsor Protocol Number: BETA-MG-01 Start Date*: 2019-03-28
    Sponsor Name:Aarhus University Hospital
    Full Title: Beta-agonist Efficacy and Tolerability as Adjuvant therapy in Myasthenia Gravis
    Medical condition: Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-000610-11 Sponsor Protocol Number: NN8226-3613 Start Date*: 2013-02-20
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003633-42 Sponsor Protocol Number: RBHIPF004 Start Date*: 2013-10-18
    Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust
    Full Title: A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease
    Medical condition: A diagnosis of connective tissue disease associated interstitial lung disease, based on internationally accepted criteria, in one of the following categories: o Systemic sclerosis o Idiopathic inte...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10022611 Interstitial lung disease PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10027754 Mixed connective tissue disease PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039710 Scleroderma PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10036102 Polymyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2022-001796-14 Sponsor Protocol Number: CYTB323G12101 Start Date*: 2023-03-20
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label, multi-center, phase 1/2 study to assess safety, efficacy and cellular kinetics of YTB323 in participants with severe, refractory systemic lupus erythematosus (srSLE).
    Medical condition: Systemic Lupus Erythematosus Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001103-31 Sponsor Protocol Number: AIT02-2001/DMID14-005 Start Date*: 2015-07-10
    Sponsor Name:Autoimmune Technologies, LLC
    Full Title: A Phase 2a, Randomized, Double-blind, Placebo-controlled Assessment of the Safety and Protective Efficacy of FF-3 Dry Powder Administered by Nasal Inhalation for 5 Days to Healthy Adult Subjects wh...
    Medical condition: Influenza A infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10022002 Influenza A virus infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000625-39 Sponsor Protocol Number: D3461C00009 Start Date*: 2016-08-18
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects with Active Systemic Lupus...
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) ES (Completed) LT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-002205-22 Sponsor Protocol Number: IM014029 Start Date*: 2020-05-01
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: "A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects with Active Systemic Lupus Erythematosus or Primary Sjögr...
    Medical condition: SLE Sub-protocol: Systemic Lupus Erythematosus pSS Sub-protocol: Primary Sjögren’s Syndrome RA Sub-protocol: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) BE (Completed) ES (Completed) PL (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004226-15 Sponsor Protocol Number: Can-Art1 Start Date*: 2018-10-26
    Sponsor Name:King Christian 10th Hospital for Rheumatology
    Full Title: CAN-ART The efficacy and safety of using cannabis derivatives cannabidiol (CBD) and tetrahydrocannabinol (THC) for the treatment of pain in patients with inflammatory arthritis (RA, AS). A rand...
    Medical condition: Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004616-12 Sponsor Protocol Number: CCDZ173X2203 Start Date*: 2016-05-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CDZ173 in patients with primary Sjögren’s syndrome
    Medical condition: Primary Sjögren's syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-019926-15 Sponsor Protocol Number: CC-10004-RA-002 Start Date*: 2011-01-27
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY, TO COMPARE THE EFFICACY AND SAFETY OF TWO DOSES OF APREMILAST (CC-10004) IN SUBJECTS WITH ACTIVE RHEUMATO...
    Medical condition: Rheumatoid arthritis, a chronic systemic autoimmune inflammatory disease characterized by persisten synovial inflammations.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004476-35 Sponsor Protocol Number: CCFZ533B2201 Start Date*: 2019-08-19
    Sponsor Name:Novartis Pharma AG
    Full Title: A 48-week, 6-arm, randomized, double-blind, placebo-controlled multicenter trial to assess the safety and efficacy of multiple CFZ533 doses administered subcutaneously in two distinct populations o...
    Medical condition: Sjögren syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) HU (Completed) GB (GB - no longer in EU/EEA) NL (Completed) GR (Completed) FR (Completed) DE (Completed) SE (Completed) AT (Completed) SI (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-004269-96 Sponsor Protocol Number: IG8801CLBP201 Start Date*: 2016-02-24
    Sponsor Name:Gador S.A.
    Full Title: A 24 weeks multicentre, randomized, double-blind, placebo-controlled, parallel group, study to evaluate the efficacy, safety and tolerability of intravenous IG-8801 20 mg and 40 mg in subjects with...
    Medical condition: non-specific Chronic Low Back Pain persisting for at least 3 months
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004859 10008837 Chronic back pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 13 03:23:56 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA